Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 21,700 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $21,480.00.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $21.74 on Friday. The company’s 50 day moving average price is $24.54 and its 200 day moving average price is $24.41. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03. The company has a market capitalization of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. BTIG Research assumed coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. Finally, Robert W. Baird lifted their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Enliven Therapeutics presently has an average rating of “Buy” and an average price target of $38.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares in the last quarter. Rhumbline Advisers grew its position in Enliven Therapeutics by 29.9% in the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after acquiring an additional 11,420 shares in the last quarter. Quest Partners LLC grew its position in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares in the last quarter. American Century Companies Inc. grew its position in Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after acquiring an additional 8,540 shares in the last quarter. Finally, Nicholas Investment Partners LP bought a new stake in Enliven Therapeutics in the second quarter worth approximately $1,310,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.